Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesFilana Therapeutics, Inc.

Filana Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.49763 USD 0.04 ( 9.92%)
Last update at 2026-11-09T15:29:00Z
VOLUME
112386
Market Cap
33.65M

Momentum Score

…

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.46
Low
0.50
High
52 Week Price Range
0.68
Low
4.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Filana Therapeutics is a Nasdaq-listed biotechnology company developing therapeutic candidates; publicly available information about its pipeline and commercial operations is limited. Long-term growth appears dependent on advancement of clinical programs, successful regulatory milestones, and potential partnerships or licensing, which may benefit investors seeking exposure to early-stage biotech upside.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.45
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-15.65M
Debt / Equity
-
ROE
-55.79%
Net Debt
-95.50M
ROCE
-128.00%
Diluted EPS TTM
-0.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -90.97M -24.34M -97.22M -76.25M -32.38M
Net income -90.97M -24.34M -97.22M -76.25M -32.38M
Selling general administrative 68.80M 71.81M 16.53M 11.99M 8.05M
Gross profit -0.94M - - - -
Reconciled depreciation 0.94M 1.13M 1.53M 1.30M -
Ebit -95.39M -142.28M -107.33M -81.48M -32.87M
Ebitda -94.45M -141.15M -105.80M -80.18M -32.33M
Depreciation and amortization 0.94M 1.13M 1.53M 1.30M 0.53M
Operating income -95.39M -141.45M -105.96M -80.02M -32.87M
Other operating expenses 95.39M 141.45M 105.96M 80.02M 32.87M
Interest income 4.62M 8.51M 7.83M 2.78M -
Net interest income 4.62M 8.51M 7.83M 2.78M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 94.45M 141.45M 105.96M 80.02M 32.87M
Cost of revenue 0.94M - - - -
Total other income expense net 4.42M 117.10M 8.74M 3.77M 0.48M
Net income from continuing ops -90.97M -24.34M -97.22M -76.25M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 118.36M 157.53M 151.66M 234.83M -
Intangible assets - 0.04M 0.18M 0.62M -
Other current assets 2.09M 0.04M 0.29M 0.16M -
Total liab 43.95M 11.83M 14.20M 7.29M -
Total stockholder equity 74.40M 145.70M 137.47M 227.54M -
Other current liab 37.44M 0.30M 0.39M 0.49M -
Common stock 0.05M - - - -
Capital stock 0.05M 0.05M 0.04M 0.04M -
Retained earnings -496.08M -405.11M -380.77M -283.55M -
Cash 95.50M 128.57M 121.14M 201.01M -
Total current liabilities 43.83M 11.75M 14.20M 7.06M -
Net debt -95.50M - - - -
Other stockholder equity 570.44M - - - -
Total current assets 97.71M 136.53M 129.63M 211.23M -
Net receivables 0.12M - - - -
Accounts payable 6.40M 7.65M 10.57M 4.02M -
Non current assets total 20.65M 21.00M 22.03M 23.61M -
Capital lease obligations - - 0.00M 0.14M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total cashflows from investing activities -0.58M - - -
Total cash from financing activities -0.24M 124.47M 2.56M 47.80M
Net income -90.97M -24.34M -97.22M -76.25M
Change in cash -33.07M 7.44M -79.88M -32.42M
Begin period cash flow 128.57M 121.14M 201.01M 233.44M
End period cash flow 95.50M 128.57M 121.14M 201.01M
Total cash from operating activities -32.25M -116.93M -82.03M -77.51M
Issuance of capital stock - 0.00M 0.00M 47.33M
Depreciation 0.94M 1.13M 1.53M 1.30M
Capital expenditures 0.58M 0.10M 0.41M 2.71M
Change in working capital 38.20M -1.83M 9.08M -4.63M
Stock based compensation 19.58M 16.29M 4.59M 2.07M
Other non cash items 19.58M - - -
Free cash flow -32.83M -117.03M -82.44M -80.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FLNA
Filana Therapeutics, Inc.		 0.04
9.92%		 0.50 - 151.52 2.54 0.55 1.33 2.08
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

6801 N. Capital of Texas Highway, Austin, TX, United States, 78731

512 501 2444

https://www.filanatx.com

17

Name Title Year Born
Mr. Richard Jon Barry CEO, President & Director 1959
Mr. Eric J. Schoen Chief Financial Officer 1968
Mr. R. Christopher Cook J.D. Chief Operating & Legal Officer 1965
Dr. George Thornton Ph.D. Senior Vice President of Technology NA
Mr. Michael Zamloot Senior Vice President of Technical Operations NA
Ms. Freda Nassif Chief Business Officer & Chief Commercial Officer 1977
Jaren Landen Chief Clinical Development Officer NA
Dr. Angelique Bordey Ph.D. Senior Vice President of Neuroscience NA
Mr. Jack Moore Ph.D. Senior Vice President of Clinical Development NA
Dr. Joseph Hulihan M.D. Chief Medical Officer 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…